10-Q: IO Biotech Reports Q1 2025 Financial Results, Cylembio Phase 3 Trial Progresses

IO Biotech, a clinical-stage biopharmaceutical company, announces its Q1 2025 financial results and provides an update on the progress of its Phase 3 trial for Cylembio in advanced melanoma.

Summary

• IO Biotech reported a net loss of $22.4 million for the three months ended March 31, 2025, compared to a net loss of $19.5 million for the same period in 2024.
• Research and development expenses increased to $16.4 million from $14.3 million year-over-year, driven by clinical trial-related activities and personnel costs.
• General and administrative expenses rose to $6.2 million from $5.9 million year-over-year, primarily due to increased professional services and personnel costs.
• Cash and cash equivalents totaled $37.1 million as of March 31, 2025.
• The company believes its existing cash and cash equivalents will be sufficient to fund operations into the second quarter of 2026, assuming the drawdown of the first three committed tranches of the EIB loan facility.
• The Phase 3 trial for Cylembio in combination with pembrolizumab for advanced melanoma is fully enrolled, with a primary endpoint readout expected in the third quarter of 2025.
• The company plans to submit a BLA to the FDA in 2025 and potentially make Cylembio available for patients in the U.S. with advanced melanoma in 2026.
• The company has plans in place to obtain sufficient additional fundraising to fulfill its operating and capital requirements for the next 12 months.
• The company has drawn down on the Tranche A loan facility in principal amount of 10.0 million on May 6, 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there is progress in clinical trials, the company is still operating at a loss and has substantial doubt about its ability to continue as a going concern. The company has plans in place to obtain sufficient additional fundraising to fulfill its operating and capital requirements for the next 12 months.

Positives

• The Phase 3 trial for Cylembio in combination with pembrolizumab for advanced melanoma is fully enrolled.
• The company expects a readout of the PFS primary endpoint in the third quarter of 2025 for the Phase 3 trial.
• IO Biotech plans to submit a BLA to the FDA in 2025 for Cylembio.
• The company believes its existing cash and cash equivalents will be sufficient to fund operations into the second quarter of 2026, assuming the drawdown of the first three committed tranches of the EIB loan facility.
• The company has drawn down on the Tranche A loan facility in principal amount of 10.0 million on May 6, 2025.

Negatives

• IO Biotech reported a net loss of $22.4 million for Q1 2025.
• The company has substantial doubt about its ability to continue as a going concern.
• The company has identified a material weakness in its internal control over financial reporting.

Risks

• The company has a limited operating history and has incurred net losses since its inception.
• All of the company's product candidates are in clinical or preclinical development.
• The company relies on third-party suppliers and contract manufacturing organizations.
• The company will need to obtain substantial additional funding to complete the development and commercialization of its product candidates.
• The company faces substantial competition.
• The company may be unable to obtain and maintain sufficient intellectual property protection.
• Public health emergencies, geopolitical conflicts or other significant domestic and international events could have a material adverse impact on the company's business.
• The price of the company's common stock may be volatile or may decline regardless of its operating performance.
• The company is subject to a variety of privacy and data security laws.
• The company has identified a material weakness in its internal control over financial reporting.
• The company's internal information technology systems, or those of its third-party contract research organizations (CROs) or other contractors or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions.

Future Outlook

The company expects its existing cash and cash equivalents will be sufficient to fund operations into the second quarter of 2026, assuming the drawdown of the first three committed tranches of the EIB loan facility. The company plans to submit a BLA to the FDA in 2025 and potentially make Cylembio available for patients in the U.S. with advanced melanoma in 2026.

Management Comments

• Management believes that its operations are scalable and, if there is a need, certain cost reduction measures may be taken to preserve cash.
• Management cannot conclude that such plans will be effectively implemented in due time to secure sufficient funds to finance operations at least through one year after the date that the financial statements are issued.

Industry Context

IO Biotech is operating in the competitive immuno-oncology space, developing novel therapeutic cancer vaccines. The company's T-win platform aims to modulate the tumor microenvironment, potentially enhancing the effectiveness of other immuno-oncology treatments.

Comparison to Industry Standards

• The company is developing IO102-IO103 in combination with pembrolizumab, which is a common strategy in the immuno-oncology field.
• The company's approach of targeting the tumor microenvironment is in contrast to previous methods that have sought to either block singular immunosuppressive pathways or to direct the immune system against specific identified antigens expressed by tumor cells.
• The company is competing with large pharmaceutical and biotechnology companies such as Amgen, AstraZeneca, BMS, Merck, Novartis, Pfizer, Moderna, Regeneron, Roche, and Roche's subsidiary Genentech, Iovance and Shenzhen.

Related Party Transactions

• Of the total proceeds from the Private Placement, legal entities of certain related parties contributed $ 33.4 million, and members of management contributed $ 0.2 million.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may be affected by potential cost reduction measures or changes in research and development programs.
• Patients may benefit from the potential approval and commercialization of Cylembio.

Next Steps

• The company expects a readout of the PFS primary endpoint in the third quarter of 2025 for the Phase 3 trial.
• IO Biotech plans to submit a BLA to the FDA in 2025 for Cylembio.
• The company will continue to seek additional funding through public financings, debt financings (including drawing on Tranche B and Tranche C EIB loan facility), collaboration agreements, strategic alliances and licensing arrangements.

Key Dates

Keywords

Cylembio, IO102-IO103, IO Biotech, Melanoma, Clinical trial, Financial results, Pembrolizumab, T-win platform, Biopharmaceutical, FDA